THURSDAY, Jan. 13, 2022 (HealthDay News) -- Living with and managing bipolar I disorder (BD-I) remains a profoundly challenging experience, according to the results of a survey released by the pharmaceutical company Alkermes and the Depression and Bipolar Support Alliance.
The survey, conducted online by The Harris Poll during August 2021 on behalf of Alkermes, included 305 U.S. adults (aged 18 to 60 years) living with BD-I and who took BD-I medication at the time of the survey or in the year prior to the survey.
Comments
Post a Comment